Balchem Announces First-Quarter 2026 Financial Results
Balchem Corporation (NASDAQ: BCPC) has announced its financial results for the first quarter of fiscal year 2026, covering the period ended March 31, 2026. The company delivered a strong start to the year, reporting record performance across key financial metrics, including net sales, net earnings, and adjusted EBITDA, while also maintaining solid cash flow generation. The results underscore Balchem’s continued momentum across its diversified portfolio of nutrition, health, and specialty products.
For the first quarter, Balchem reported net sales of $270.7 million, representing an 8.1% increase compared to the same period in the previous year. This growth reflects positive contributions from all three of the company’s reporting segments, highlighting balanced expansion across its business lines. The company’s ability to drive consistent top-line growth demonstrates resilience in demand for its core offerings and the effectiveness of its strategic initiatives.
Net earnings for the quarter reached $40.3 million on a GAAP basis, marking an 8.7% year-over-year increase. Profitability improvements were also evident in adjusted EBITDA, which rose to $74.3 million, up 12.1% from the prior-year quarter. This outpaced revenue growth, indicating enhanced operational efficiency and favorable product mix. The company’s margin expansion reflects disciplined cost management and ongoing investments in higher-value solutions.
Earnings per share (EPS) further reinforced Balchem’s solid financial performance. GAAP EPS came in at $1.25, compared to $1.13 in the first quarter of 2025. On an adjusted basis, EPS was $1.33, up from $1.22 in the prior-year period. These gains highlight the company’s consistent ability to translate revenue growth into shareholder value.
Cash flow generation remained robust during the quarter. Balchem reported cash flows from operations of $40.1 million, while free cash flow totaled $33.8 million. Strong cash generation provides the company with flexibility to reinvest in growth initiatives, pursue strategic opportunities, and return value to shareholders.
Commenting on the results, Chairman, President, and Chief Executive Officer Ted Harris described the first quarter as an excellent start to 2026. He emphasized that the company achieved sales and earnings growth across all three reporting segments, while also delivering record first-quarter results in net sales, adjusted EBITDA, and net earnings. Harris also highlighted the strength of the company’s cash flow, reinforcing Balchem’s financial health and operational discipline.
Across its reporting segments, Balchem demonstrated broad-based growth. Each segment contributed to the overall increase in sales and operating earnings, reflecting the company’s diversified business model and its ability to capture opportunities in multiple end markets, including human nutrition, animal nutrition, and specialty products. This diversified approach helps mitigate risk while enabling sustained growth.
Beyond financial performance, Balchem also reported notable developments in research and sustainability during the quarter. One of the key highlights was the publication of new clinical research exploring the role of choline in cognitive health. The study, published in the peer-reviewed journal Nutrients, utilized Balchem’s proprietary VitaCholine® ingredient. Using functional magnetic resonance imaging (fMRI), researchers found that choline may influence brain network efficiency in post-menopausal women.
The study specifically examined working memory-related brain activation and functional connectivity, suggesting that VitaCholine® could play a role in supporting cognitive function in older adults. These findings contribute to a growing body of evidence supporting the importance of choline in brain health and reinforce Balchem’s position as a leader in science-backed nutritional ingredients. The research also aligns with broader trends in the health and wellness sector, where demand for cognitive health solutions continues to rise.
In addition to advancements in scientific research, Balchem reaffirmed its commitment to sustainability and responsible business practices. On April 22, 2026, the company released its 2025 Sustainability Report, outlining its progress and initiatives across environmental, social, and governance (ESG) priorities. The report highlights Balchem’s efforts to develop innovative solutions that address global health and nutrition challenges while maintaining high standards of operational excellence.
The sustainability report reflects the company’s broader vision of making the world a healthier place. It also emphasizes Balchem’s role as a responsible steward of its stakeholders, including employees, customers, shareholders, and the communities in which it operates. By integrating sustainability into its business strategy, the company aims to drive long-term value creation while addressing critical global issues.
Balchem’s ongoing investments in innovation, research, and sustainability position it well for future growth. The company continues to focus on delivering high-quality, science-based solutions that meet evolving customer needs. At the same time, its disciplined financial management and strong cash flow generation provide a solid foundation for continued expansion.
Looking ahead, Balchem remains optimistic about its growth prospects for the remainder of 2026. The company’s strong first-quarter performance sets a positive tone for the year, supported by favorable market trends, a robust product portfolio, and ongoing innovation. Management’s focus on operational excellence and strategic execution is expected to drive continued value creation.
To provide further insights into its first-quarter performance, Balchem has scheduled a quarterly conference call for April 30, 2026, at 11:00 AM Eastern Time. The call will be hosted by CEO Ted Harris and Chief Financial Officer Martin Bengtsson. During the call, management will review financial results, discuss business performance, and address questions from institutional investors, analysts, and members of the financial community.
The conference call will be accessible via telephone and webcast, allowing investors and the public to participate. A replay of the webcast will also be made available shortly after the conclusion of the call and will remain accessible for one year, ensuring transparency and ongoing engagement with stakeholders.
Overall, Balchem’s first-quarter 2026 results highlight a strong combination of financial performance, operational execution, and strategic progress. With record results, expanding margins, and continued innovation in both science and sustainability, the company is well-positioned to build on its momentum and deliver sustained growth throughout the year.
Source Link:https://balchem.com/
